Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Administrative data

Link to relevant study record(s)

Description of key information

No experimental data are available on toxicokinetics for this substance. Therefore, a qualitative assessment of the absorption, distribution/accumulation, metabolism and elimination is performed on the basis of the physicochemical properties of the substance, toxicological data and available information from public literature on the substance and relevant information on other 'water-soluble' cerium salts (e.g. cerium trichloride).
A summary of the qualitative assessment is included in the discussion. The full assessment is attached to this section.

Key value for chemical safety assessment

Bioaccumulation potential:
low bioaccumulation potential
Absorption rate - oral (%):
10
Absorption rate - dermal (%):
1
Absorption rate - inhalation (%):
10

Additional information

No toxicokinetic experimental data (animal or human studies/information) are currently available on this water-soluble cerium salt.Therefore, a toxicokinetic assessment is done based on the physicochemical characteristics of cerium trinitrate, on toxicological information available on this compound but also on information available on other water-soluble cerium compounds. A summary of the qualitative assessment is included in this section. The full assessment (including the references) is attached to this section.

 

Indeed, it is generally assumed that for metals and metal compounds, the metal ion (regardless of the counterparts of the metal in the respective metal compounds), is responsible for the observed systemic toxicity. Information on other cerium compounds can thus be used as long as their inherent properties are taken into account. In addition, as indicated in ECHA’s guidance on QSAR and grouping of chemicals (ECHA, 2008), comparison of the water solubility can be used as surrogate to assess the bioavailability of metals, metal compounds and other inorganic compounds. In the case of cerium salts, this simplistic approach assumes that a specific very water-soluble metal-containing compound (target chemical) will show the same hazards as other very water-soluble metal-containing compounds with the same specific metal ion (HERAG, 2007). Therefore, although studies evaluating the toxicokinetic behavior following exposure to cerium trinitrate (a water-soluble cerium salt) are not available, information on other water-soluble cerium salts as cerium chloride can be used to estimate the absorption and bioavailability of a common metal ion (Ce+3).

 

The toxicokinetic behaviour of the counter ion is thus not evaluated.

 

This assessment is therefore mainly based on information from the toxicological review of cerium compounds done by U.S. EPA (2009) and includes the references used in the original document.

 

Absorption

Oral/Gastro-intestinal (GI) absorption

Cerium trinitrate is a solid inorganic salt of cerium, a member of the lanthanide series of metals. When present in compounds, cerium exists in both the trivalent Ce+3 and the tetravalent Ce+4 state. Cerium in cerium trinitrate is in Ce+3 oxidation state. The molecular weight of Cerium trinitrate is 326.13 g/mol (anhydrous form).

Cerium trinitrate is a very soluble compound in pure water (> 600 g/L, pH not reported). Based on this information, it could be expected that cerium trinitrate will readily dissolve into the gastric fluid. However, its high water solubility is influenced by the pH. It is also anticipated that the differences of solubility were (or at least partly) explained by the formation of low soluble forms of cerium (e.g. cerium hydroxides) at high pH. This decrease in solubility is also observed in other water-soluble cerium salts. In physiologically relevant aqueous media moreover precipitation of other insoluble complexes may be expected, such as rare earth phosphates, with formation of the latter also increasing with increasing pH. Therefore, once in the intestines, it is expected that the solubility of the cerium trinitrate rapidly and significantly decreases due to the pH increase of the intestinal fluid and thus the potential absorption will be significantly hampered.

In general, absorption from the gastro-intestinal lumen can occur by two mechanisms: by passive diffusion and/or by specialized transport system. For cerium trinitrate and its metal ion Ce+3, it would not be expected to readily diffuse across biological membranes. For rare earth elements, there is no information available on specialized mechanism of transport. In addition it is believed that the free metal cation (Ce+3) will not exist at a significant concentration in solution due to the decreased solubility under the pH conditions in the gastrointestinal lumen.

Based on the physicochemical properties of the cerium trinitrate (i.e. decreased solubility at the intestinal tract and the anticipated hampered diffusion as ionized substance), low absorption is expected.

As indicated previously, comparison of the water solubility can be used as surrogate to assess the bioavailability of metals, metal compounds and other inorganics compounds. Therefore information on other water-soluble cerium salts as cerium chloride, is used to estimate the absorption and bioavailability of the common metal ion Ce+3. Based on the information available on the absorption after oral exposure to the water-soluble cerium trichloride, similar very low absorption is expected after oral exposure to cerium trinitrate.

This assumption is also supported by the low toxicity of cerium trinitrate after both single and repeated exposure.

Based on the anticipated low absorption due to the physicochemical properties of cerium trinitrate (ie. decrease in solubility with the pH and the hampered diffusion when the substance is ionized), on the animal data with cerium trichloride and the low toxicity observed on the available toxicological tests with cerium trinitrate, the oral absorption factor for cerium trinitrate is estimated to be 10% for risk assessment purposes.

 

Respiratory absorption 

Low exposure to cerium trinitrate is expected based on the inherent properties of the substance. So, as the vapour pressure of the cerium trinitrate is too low to enable reliable measurements below its decomposition temperature, it is not likely that cerium trinitrate is available for inhalation as a vapour. Moreover, no particle size distribution test has been performed with cerium trinitrate due to the special properties of the substance. Thus, as the formation of respirable suspended particulate matter is unlikely, human exposure by inhalation is considered not significant. Despite the fact that the exposure is considered not significant, the absorption of the potentially inhaled particles of cerium trinitrate is assessed here below.

Cerium trinitrate is a very soluble compound in pure water. However its high water solubility is influenced by the pH as discussed previously. Therefore, once deposited on the walls of the airways, it is expected that the solubility of the cerium trinitrate significantly decreases due to the pH of the lung mucosae (the composition of the lung mucosae is mainly water with a pH about 6.6 in healthy individuals) and absorption or translocation from the lung to the circulation is expected to be minimal.

Deposited material in the alveolar region may be engulfed by alveolar macrophages as the substance will not be able to dissolve. The macrophages will then either translocate particles to the ciliated airways or carry particles into the pulmonary interstitium and lymphoid tissues. Deposited substances may be also transported out of the respiratory tract and swallowed through the action of clearance mechanisms, especially those which settle in the tracheo-bronchial region. In that last case the substance needs to be considered as contributing to the oral/GI absorption rather than to the inhalation rate.

As stated before, it has been shown that several metals can cross cell membranes by specific carriers and ion channels intended for endogenous substrates. But, for rare earth elements, there is no information available on such mechanism of transport. In addition, it is believed that the free metal cation (Ce+3) will not exist at a significant concentration in solution due to the decreased solubility under the pH conditions in the pulmonary mucosae.

Although toxicokinetic studies evaluating the absorption of cerium trinitrate following inhalation are not available, information on other water-soluble cerium salts can be used to support the evaluation of the absorption of this substance. Therefore the limited animal data available regarding total deposition and absorption of cerium trichloride within the respiratory tract is used to estimate the absorption following inhalation exposure to cerium trinitrate (See attached document).

Based on the anticipated low solubility of cerium trinitrate at physiological pHs and the available animal data on cerium trichloride, the respiratory absorption factor for cerium trinitrate is set at 10% for risk assessment purposes.

Dermal absorption

Studies evaluating absorption following dermal exposure in humans or animals are not available. Therefore a qualitative assessment of the toxicokinetic behavior based on cerium trinitrate physicochemical properties is performed, taking other toxicological data on this substance (obtained after dermal exposure) into consideration.

As cerium trinitrate is a solid that appears as a clump, the potential human exposure by the dermal route is expected to be low.

Cerium is not expected to cross the intact skin after exposure to water-soluble cerium trinitrate. This assumption is based on the qualitative assessment of the physicochemical properties of the substance: cerium would have to dissolve in the moisture on the skin, however, as the solubility of cerium trinitrate rapidly decrease at physiologically relevant pH, no significant uptake by the skin is expected. Although a part of the substance was dissolved, the amount would significantly decrease with time due to the epidermis buffer potential and the formation of unsoluble forms of cerium (e.g. cerium hydroxides) at high pH. Moreover, and prior diffusion through the skin, dissociation to the metal cation is required but for metals and their inorganic compounds partition coefficients are irrelevant. Therefore it is unlikely that cerium trinitrate crosses the stratum corneum.

Cerium trinitrate is not a skin irritant nor a skin sensitizer and thus it is not expected that low dermal absorption is enhanced by the irritant/sensitizer effect on the skin. This assumption is also supported by the low toxicity of cerium trinitrate after single dermal exposure showed in an acute dermal toxicity study.

No toxicological information is available for animals after repeated exposure via dermal route.

In the absence of measured data on dermal absorption, current ECHA guidance (2012) suggests the assignment of either 10% or 100% default dermal absorption rates. However, the currently available scientific evidence on dermal absorption of some metals (e.g. Zn sulphate, Ni acetate; based on the experience from previous EU risk assessments) indicates that lower figures than the lowest proposed default value of 10 % could be expected (HERAG, 2007).

Based on the inherent properties of cerium trinitrate, the toxicological data available and the experience from HERAG, very low dermal absorption is expected. Therefore, a dermal absorption factor of 1% is suggested for risk assessment purposes.

Distribution/accumulation

 

Studies evaluating the distribution of cerium trinitrate in humans or animals are not available, but there is information on other very soluble cerium salts as cerium trichloride. Summarizing, and considering that the irritant potential of the cerium trinitrate to the mucosae after oral or inhalation exposure is estimated less important that the cerium trichloride, the penetration of a small amount of the substance can be facilitated. This phenomenon is covered by the proposed absorption factors. Once cerium is bioavailable, the substance will tend to distribute to the bone, kidney, liver, spleen and lung as confirmed by the abovementioned studies, however the amount distributed in each organ compared to the administer dose is unknown.

Studies with cerium trichloride seem to indicate that the distributed cerium would be localized in the cell, particularly in the lysosomes, where it is concentrated and precipitated in an insoluble form in association with phosphorus.

Regarding the potential accumulation of bioavailable cerium after exposure to cerium trinitrate, the available animal information is insufficient to provide adequate data. Therefore, and based on all the above mentioned data, accumulation of the very small bioavailable fraction of cerium after exposure to cerium trinitrate cannot be totally excluded. However, the assessment of bioaccumulation potential in aquatic and terrestrial organisms of cerium trinitrate included in this dossier indicates that the substance has a low potential for bioaccumulation and that the bioaccumulation decreases when ascending the food chain. Thus, for risk assessment purposes it is proposed to consider that cerium trinitrate shows low accumulation potential in humans.

Metabolism

As an element, cerium is neither created nor destroyed within the body. Experimental data have not demonstrated a change in the oxidation state of the cerium molecule in the body.

Cerium trinitrate was demonstrated not to be mutagenic in vitro, in the absence and presence of metabolic activation.

Studies evaluating the potential impact on general metabolism after exposure to cerium trichloride are available. These data indicate that it can have an effect in the activity of cytochrome isoenzymes .

Excretion

Studies evaluating the excretion of bioavailable cerium trinitrate in humans or animals are not available. Although quantitative estimates of cerium elimination are rare, it appears that the primary route of elimination for cerium, whether inhaled, ingested, or injected, is through the feces, with small (generally < 10%) amounts eliminated in the urine (Lustgarten et al., 1976; Durbin et al., 1956). It has been suggested that the fecel excretion of systematically absorbed cerium is due to elimination in the bile (Lustgarten et al., 1976), since hepatic clearance was due primarily to biliary function.

References

Arvela, P; Karki, NT. (1971) Effect of cerium on drug metabolism activity in rat liver. Experientia 27(10):1189–1190.

Arvela, P; Kraul, H; Stenback, F; et al. (1991) The cerium-induced liver injury and oxidative drug metabolism in Dba/2 and C57bl/6 mice (Finland). Toxicology 69(1):1–9. 

Baltussen (2007). Determination of the vapour pressure of cerium nitrate 99.5 crystallised by isothermal thermogravimetry. Notox B.V. Technical report.

Beckett (2007). Routes of exposure, dose and metabolism of metals. Chapter 3 of Handbook on the toxicology of metals (3rd Edition).

Berry, JP; Meignan, M; Escaig, F; et al.(1988) Inhaled soluble aerosols insolubilised by lysosomes of alveolar cells. Application to some toxic compounds; electron microprobe and ion microprobe studies. Toxicology 52(1–2):127–139.

Berry, JP; Masse, R; Escaig, F; et al. (1989) Intracellular localization of cerium. A microanalytical study using an electron microprobe and ionic microanalysis. Hum Toxicol 8(6):511–520.

Berry, JP. (1996) The role of lysosomes in the selective concentration of mineral elements. A microanalytical study. Cell Mol Biol 42(3):395–411.

Berry, JP; Zhang, L; Galle, P; et al. (1997) Role of alveolar macrophage lysosomes in metal detoxification. Microscop Res Technol 36:313–323.

Boecker, BB; Cuddihy, RG. (1974) Toxicity of 144Ce Inhaled as 144CeCl3 by the beagle: metabolism and dosimetry. Radiat Res 60(1):133–154.

Bradshaw (2013). Acute dermal toxicity (limit test) in the rat. Harlan Laboratories Ltd. Technical report.

Braun (2013). Cerium trinitrate: combined repeated dose toxicity study with reproduction/developmental toxicity screening test in the Han Wistar Rat. Harlan Laboratories Ltd. Technical report.

Bruce (1963). The Acute Mammalian Toxicity of Rare Earth Nitrates and Oxides. Toxicol. Appl. Pharmac., 5, 750-759.

Cornelis (2011). Solubility and batch retention of CeO2 nanoparticles in soils. Environ. Sci. Technol.: 45, 2777-2782.

Durbin et al. (1956). Metabolism of the lanthanons in the rat. Proc Soc Exper Biol Med 91: 78 -85.

ECHA guidance on QSAR and grouping of chemicals (ECHA Chapter R.6, 2008)

ECHA guidance on information requirements and chemical safety assessment (ECHA Chapter R.7.c, 2012)

Galle, P; Berry, JP; Galle, C. (1992) Role of alveolar macrophages in precipitation of mineral elements inhaled as soluble aerosols. Environ Health Perspect 97:145–147.

Hargitai (2017) Cerium trinitrate: A dose range finding toxicity study by oral gavage administration in pregnant Hannover Wistar rats. CiToxLAB Hungary Ltd., Study report

Hargitai (2017) Cerium trinitrate: A prenatal development toxicity study by oral gavage administration in pregnant Hannover Wistar rats. CiToxLAB Hungary Ltd., Study report

Health risk assessment guidance for metals (HERAG) (2007) Assessment of occupational dermal exposure and dermal absorption for metals and inorganic metal compounds. EBRC Consulting GmbH.

Henzell (2013). Cerium trinitrate: local lymph node assay in the mouse. Harlan Laboratories. Technical report.

Inaba, J; Lengemann, FW. (1972) Intestinal uptake and whole-body retention of 141Ce by suckling rats. Health Phys 22:169–175.

Kawagoe (2008). Acute effects on the lung and the liver of oral administration of cerium chloride on

adult, neonatal and fetal mice. Journal of trace elements in medicine and biology 22, 59-65.

Kawagoe, M; Hirasawa, F; Wang, SC; et al.(2005) Orally administered rare earth element cerium induces metallothionein synthesis and increases glutathione in the mouse liver. Life Sci 77:922–937.

Kostial, K; Kargacin, B; Blanusa, M; et al. (1989b) Location of mercury, cerium, and cadmium in the gut of suckling and weaned rats. Period Biol 91(3):321–326.

Kostial, K; Kargacin, B; Landeka, M. (1989a) Gut retention of metals in rats. Biol Trace Elem Res 21:213–218.

Lustgarten, CS; Boecker, BB; Cuddihy, RG; et al. (1976) Biliary excretion of 144Ce after inhalation of 144Ce citrate in rats and Syrian hamsters. III. Annual report of the Inhalation Toxicology Research Institute. Lovelace Foundation for Medical Education and Research, Albuqueque, NM; pp. 84–87.

Morgan, BN; Thomas, RG; McClellan, RO. (1970) Influence of chemical state of cerium-144 on its metabolism following inhalation by mice. Am Ind Hyg Assoc J 31(4):479–484.

Nakamura (1997). Differences in behavior among the chlorides of seven rare earth elements administered intravenously to rats. Fundamental and applied toxicology 37, 106-116.

Salonpää, P; Iscan, M; Pasanen, M; et al. (1992) Cerium-induced strain-dependent increase in Cyp2a-4/5 (cytochrome P4502a-4/5) expression in the liver and kidneys of inbred mice. Biochem Pharmacol 44(7):1269–1274.

Shiraishi, Y; Ichikawa, R. (1972) Absorption and retention of 144Ce and 95Zr-95Nb in newborn, juvenile and adult rats. Health Phys 22:373–378.

Stineman, CH; Massaro, EJ; Lown, BA; et al. (1978) Cerium tissue/organ distribution and alterations in open field and exploratory behavior following acute exposure of the mouse to cerium (citrate). J Environ Pathol Toxicol 2(2):553–570.

Sturbaum, B; Brooks, AL; McClellan, RO. (1970) Tissue distribution and dosimetry of 144Ce in Chinese hamsters. Radiat Res 44:359–367.

U.S. Environmental protection agency (2009). Toxicological review of cerium oxide and cerium compounds in support of summary information on the integrated risk information system (IRIS).

Weissenfeld ( 2006). Determination of the water solubility of cerium nitrate 99.5 cristallised. RCC Ltd. Technical report. 

Wiener-Schmuck, M; Lind, I; Polzer, G; et al. (1990) In vivo and in vitro effects of rare earth compounds. J Aerosol Sci 21(1):S505–S508.